Detalhe da pesquisa
1.
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
J Neurol Neurosurg Psychiatry
; 2024 Mar 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38453478
2.
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
J Neurol Neurosurg Psychiatry
; 2024 Jan 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38242680
3.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry
; 2024 Apr 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38569872
4.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37369086
5.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry
; 94(12): 984-991, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37414538
6.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37068931
7.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37414534
8.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
; 29(7): 875-883, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36851894
9.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36800908
10.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36692895
11.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler
; 28(6): 958-969, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34623947
12.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
; 28(11): 1752-1761, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35373638
13.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35582938
14.
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Mult Scler
; 27(5): 695-705, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32639855
15.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32538713
16.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33423618
17.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32947619
18.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32386427
19.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler
; 26(1): 79-90, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31397221
20.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 90(4): 458-468, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30636699